- Home
- ELUT vs APOG Comparison
ELUT vs APOG Comparison
Compare ELUT & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELUT
- APOG
- Stock Information
- Founded
- ELUT 2015
- APOG 1949
- Country
- ELUT United States
- APOG United States
- Employees
- ELUT N/A
- APOG N/A
- Industry
- ELUT Medical Specialities
- APOG Auto Parts:O.E.M.
- Sector
- ELUT Health Care
- APOG Consumer Discretionary
- Exchange
- ELUT Nasdaq
- APOG Nasdaq
- Market Cap
- ELUT 94.0M
- APOG N/A
- IPO Year
- ELUT 2020
- APOG N/A
- Fundamental
- Price
- ELUT $2.05
- APOG $40.13
- Analyst Decision
- ELUT Strong Buy
- APOG Hold
- Analyst Count
- ELUT 2
- APOG 1
- Target Price
- ELUT $9.00
- APOG $62.00
- AVG Volume (30 Days)
- ELUT 40.2K
- APOG 203.8K
- Earning Date
- ELUT 05-08-2025
- APOG 06-26-2025
- Dividend Yield
- ELUT N/A
- APOG 2.59%
- EPS Growth
- ELUT N/A
- APOG N/A
- EPS
- ELUT N/A
- APOG 3.89
- Revenue
- ELUT $24,375,000.00
- APOG $1,360,994,000.00
- Revenue This Year
- ELUT $39.35
- APOG $2.57
- Revenue Next Year
- ELUT $61.26
- APOG $1.79
- P/E Ratio
- ELUT N/A
- APOG $9.95
- Revenue Growth
- ELUT N/A
- APOG N/A
- 52 Week Low
- ELUT $1.79
- APOG $38.67
- 52 Week High
- ELUT $5.24
- APOG $87.93
- Technical
- Relative Strength Index (RSI)
- ELUT 39.97
- APOG 40.21
- Support Level
- ELUT $1.79
- APOG $38.45
- Resistance Level
- ELUT $2.07
- APOG $41.46
- Average True Range (ATR)
- ELUT 0.20
- APOG 1.50
- MACD
- ELUT -0.00
- APOG -0.11
- Stochastic Oscillator
- ELUT 33.08
- APOG 22.30
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.